MedTrace Logo

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

NCT00390325 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-02-06

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally advanced), or has returned after a period of improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Conditions

  • Hereditary Thyroid Gland Medullary Carcinoma
  • Locally Advanced Thyroid Gland Medullary Carcinoma
  • Multiple Endocrine Neoplasia Type 2A
  • Multiple Endocrine Neoplasia Type 2B
  • Recurrent Thyroid Gland Medullary Carcinoma
  • Sporadic Thyroid Gland Medullary Carcinoma
  • Stage III Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7

Interventions

DRUG

Sorafenib Tosylate

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Bhavana Konda · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-03
Primary Completion
2017-01-30
Completion
2022-12-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390325 on ClinicalTrials.gov